INT44323

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 32
Total Number 39
Disease Relevance 24.88
Pain Relevance 3.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (F8) oxidoreductase activity (F8) extracellular region (F8)
cell adhesion (F8) plasma membrane (F8)
Anatomy Link Frequency
plasma 5
platelet 2
blood 1
smooth muscle 1
F8 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 190 100.00 Very High Very High Very High
Inflammation 76 99.56 Very High Very High Very High
headache 8 96.92 Very High Very High Very High
Pain 16 94.16 High High
abdominal pain 9 87.24 High High
Paracetamol 4 78.56 Quite High
alcohol 4 78.08 Quite High
ischemia 4 75.00 Quite High
cytokine 3 74.76 Quite High
Inflammatory response 15 56.40 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 89 99.92 Very High Very High Very High
Disease 76 99.88 Very High Very High Very High
Thyroid Disease 4 99.88 Very High Very High Very High
Graves' Ophthalmopathy 4 99.70 Very High Very High Very High
Hemorrhage 219 99.68 Very High Very High Very High
Cv General 3 Under Development 16 99.66 Very High Very High Very High
Thrombophilia 331 99.52 Very High Very High Very High
Thrombosis Related Under Development 125 99.42 Very High Very High Very High
Injury 55 99.32 Very High Very High Very High
Coagulation Disorder 458 99.10 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Laboratory tests revealed elevated plasma factor VIII coagulant activity.
Positive_regulation (elevated) of plasma factor VIII in plasma
1) Confidence 0.60 Published 2007 Journal Int. J. Urol. Section Abstract Doc Link 17645617 Disease Relevance 0.41 Pain Relevance 0.29
This patient represents the first reported case of deep dorsal penile thrombophlebitis associated with elevated plasma factor VIII coagulant activity, which is an independent risk factor of recurrent venous thromboembolism and superficial thrombophlebitis.
Positive_regulation (elevated) of plasma factor VIII in plasma associated with cva and thrombosis related under development
2) Confidence 0.60 Published 2007 Journal Int. J. Urol. Section Abstract Doc Link 17645617 Disease Relevance 0.61 Pain Relevance 0.34
Elevated plasma factor VIII coagulant activity presenting with thrombophlebitis of the deep dorsal vein of the penis.
Positive_regulation (Elevated) of plasma factor VIII in plasma associated with cva
3) Confidence 0.60 Published 2007 Journal Int. J. Urol. Section Title Doc Link 17645617 Disease Relevance 0.41 Pain Relevance 0.35
Factor VIII and von Willebrand factor were reproducibly elevated to high activity levels over a period of 12 months in absence of acute or chronic inflammatory reaction.
Positive_regulation (elevated) of Factor VIII associated with inflammation
4) Confidence 0.53 Published 2002 Journal Z Gastroenterol Section Abstract Doc Link 12055664 Disease Relevance 0.84 Pain Relevance 0.17
Increased levels of factor VIII and von Willebrand factor may play a pathogenetic role in the development of portal, splenic, and mesenteric thrombosis.
Positive_regulation (Increased) of factor VIII associated with thrombosis
5) Confidence 0.53 Published 2002 Journal Z Gastroenterol Section Abstract Doc Link 12055664 Disease Relevance 0.89 Pain Relevance 0.17
Thrombophilia screening demonstrated elevated factor VIII levels (206 %) and von Willebrand factor levels (> 440 %).
Positive_regulation (elevated) of factor VIII associated with thrombophilia
6) Confidence 0.53 Published 2002 Journal Z Gastroenterol Section Abstract Doc Link 12055664 Disease Relevance 0.88 Pain Relevance 0.17
The requirements for factor VIII (AHF) or factor IX (PTC) of hemophilic patients undergoing dental extractions were evaluated to determine the minimum effective regimen.
Positive_regulation (requirements) of AHF
7) Confidence 0.49 Published 1984 Journal Am. J. Hematol. Section Abstract Doc Link 6421150 Disease Relevance 0.07 Pain Relevance 0
The atypical giant cells were positive for FVIII antibody staining.
Positive_regulation (positive) of FVIII
8) Confidence 0.49 Published 2002 Journal Ann Diagn Pathol Section Abstract Doc Link 12089730 Disease Relevance 1.42 Pain Relevance 0.08
Immunohistochemistry showed that the neoplastic cells were positive for smooth muscle actin and for h-caldesmon and negative for CD34, calponin, FVIII-associated antigen, S100, EMA and cytokeratin AE1 AE3.
Positive_regulation (negative) of FVIII in smooth muscle
9) Confidence 0.49 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC2221972 Disease Relevance 0.72 Pain Relevance 0.04
PEGLip-formulated FVIII
Positive_regulation (formulated) of FVIII
10) Confidence 0.46 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
In general, treatments with PEGLip-formulated FVIII and FVIIa were well tolerated.
Positive_regulation (formulated) of FVIII
11) Confidence 0.46 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.54 Pain Relevance 0
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
Positive_regulation (derived) of FVIII in plasma associated with coagulation disorder
12) Confidence 0.46 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.87 Pain Relevance 0.04
Replacement treatment is complicated by the emergence of antibodies that inhibit the activity of the injected protein.14 Approximately 20%–40% of hemophilia A patients and 2%–3% of hemophilia B patients develop inhibitors.15,16 As expected, the more profound mutations resulting in the lack of circulating FVIII or FIX are associated with higher risk of inhibitor development.17 Neutralizing or inactivating autoantibodies to FVIII may also develop in patients without a history of coagulation factor deficiency.
Positive_regulation (circulating) of FVIII associated with coagulation disorder
13) Confidence 0.46 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.74 Pain Relevance 0
This was shown by in-vitro binding of PEGLip-formulated FVIII to vWF.45 Thus binding of PEGLip to FVIII does not change the protein’s biological properties.
Positive_regulation (formulated) of FVIII
14) Confidence 0.46 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
We studied the differential increase in FVIIIc and FVIII R:Ag after the intravenous infusion of 0.30 micrograms/kg DDAVP in 20 obligate hemophilia A carriers and in 20 female controls.
Positive_regulation (increase) of FVIII associated with coagulation disorder
15) Confidence 0.45 Published 1984 Journal J. Pediatr. Section Abstract Doc Link 6425482 Disease Relevance 0.22 Pain Relevance 0
The recognition of the protective effects of early low-dose prophylaxis has led many centers to pursue an incremental FVIII dosing approach in which patients initially receive once a week prophylaxis unless bleeding develops.77 Over a several months period, the infusion frequency is then increased to twice or three times a week therapy.


Positive_regulation (incremental) of FVIII associated with hemorrhage
16) Confidence 0.44 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835555 Disease Relevance 0.43 Pain Relevance 0
This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (> or = 100 prior exposure days) with severe (<2% FVIII) hemophilia A in North America (NA) and Europe (EU).
Positive_regulation (sucrose-formulated) of rFVIII associated with coagulation disorder
17) Confidence 0.44 Published 2000 Journal Thromb. Haemost. Section Abstract Doc Link 10896230 Disease Relevance 0.17 Pain Relevance 0
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
Positive_regulation (formulated) of factor VIII associated with coagulation disorder and cva
18) Confidence 0.44 Published 2000 Journal Thromb. Haemost. Section Title Doc Link 10896230 Disease Relevance 0.17 Pain Relevance 0.10
This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (> or = 100 prior exposure days) with severe (<2% FVIII) hemophilia A in North America (NA) and Europe (EU).
Positive_regulation (sucrose-formulated) of rFVIII associated with coagulation disorder
19) Confidence 0.44 Published 2000 Journal Thromb. Haemost. Section Abstract Doc Link 10896230 Disease Relevance 0.17 Pain Relevance 0
There are only six cases of cerebral venous thrombosis due to hyperthyroidism with increased factor VIII level.
Positive_regulation (increased) of factor VIII associated with thyroid disease and thrombosis related under development
20) Confidence 0.43 Published 2006 Journal Rinsho Shinkeigaku Section Abstract Doc Link 16768094 Disease Relevance 1.01 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox